No. More positive attitudes after using AMIE are a meaningful finding about patient experience, but they do not establish clinical benefit or appropriate reliance on every answer. The study's published abstract, released on 8 October 2026, reports improved attitudes after the AI interaction that remained elevated after the clinical appointment. That finding should not be relabelled as diagnostic validation.
The patient perspective also contains more than one question. Someone can feel heard while remaining uncertain about an answer, or value the convenience while worrying about confidentiality. BIDMC's report dated 9 October 2026 identifies continuing concerns about confidentiality and the chatbot's honesty and trustworthiness alongside favourable experiences.
What changed after the interaction?
The March 2026 methods describe repeated assessment using the General Attitudes towards AI Scale before the AI conversation, afterwards and following the primary-care appointment. This measured attitudes towards AI, not a direct test of whether each participant understood every clinical statement correctly. The preprint provides that methodological distinction.
The positive shift suggests that experience with the supervised system changed how participating patients viewed AI. It cannot establish how patients who declined participation would have responded, or how the same people would judge an unsupervised service with different responsibilities.
The evaluated experience included an existing appointment and a physician safety supervisor. Those arrangements matter when interpreting reassurance or confidence. A patient who knows a clinician will still assess them is not necessarily expressing willingness to rely on software as the sole source of care.
Feeling heard is different from believing the diagnosis
Consider a fictional patient who appreciates having time to describe symptoms without feeling hurried. They may rate the conversation highly because their account felt complete. That does not tell us whether the proposed differential was correct or whether the patient understood the uncertainty around it.
Another fictional patient may regard an answer as medically plausible but hesitate to share sensitive information because they do not understand who can access it. Their concern is not necessarily about the model's conversational ability. Improving the wording of a response would not, by itself, answer the data-handling question.
A third may trust the clinical service while disliking the interface. Treating all these experiences as one satisfaction score would obscure what needs improving. These are constructed examples, not descriptions of named AMIE participants.
Maximum trust is the wrong design target
The editorial goal should be appropriate reliance: patients understand what the tool can contribute, recognise the limits of the encounter and know when a person should take over. That may involve confidence in some functions and caution about others.
A patient can reasonably trust that a system will organise their account while still expecting the clinician to examine a new finding. Similarly, confidence that a message has been recorded is different from believing that a diagnosis has been established. The interface should not quietly blur those expectations.
This argument does not assume that people are inherently unable to use medical AI sensibly. It asks whether the service makes sensible use possible. Clear explanations of human review, uncertainty and the next step are part of that design, not optional disclaimers after the interaction.
For UK practice, the GMC's decision-making and consent guidance, checked on 10 October 2026, emphasises dialogue and information relevant to the individual. It is a professional reference for the discussion, not a regulatory judgement about the US research service.
A patient questionnaire that tests understanding
A future evaluation could retain a validated attitude scale while adding specific comprehension questions. The following is an original proposed questionnaire, not a validated instrument or a description of questions used in the AMIE trial.
| Proposed question | What the answer could reveal |
|---|---|
| What do you think the AI established about your symptoms? | Whether possibilities were mistaken for confirmed findings |
| What remains uncertain after this conversation? | Whether the limits of the assessment were understood |
| What do you expect your clinician to check? | Whether the roles of AI and clinician are clear |
| What should you do if your situation changes before the appointment? | Whether the patient understands the route back to care |
| Who do you believe can access what you entered? | Whether privacy expectations match the service's actual arrangements |
| How would you request human help or stop using the AI? | Whether choice and escalation are practically available |
Open answers are useful because a patient may agree with a reassuring statement without interpreting it as the researcher intended. An evaluator should examine the content of the response rather than score willingness to praise the system.
Any such questionnaire would itself need development and testing before being treated as a validated measure. Its role here is to make the next research question concrete.
Preserve the option not to participate
The March 2026 recruitment description states that participation was voluntary and that declining would not affect access to care. That is part of the context in which the experience findings were obtained. The study methods should not be simplified into a claim about acceptance of mandatory AI intake.
A service that makes an automated conversation the only practical route to an appointment changes the patient's choice. Someone completing the process may be complying with an access requirement rather than expressing confidence in the technology. Completion and acceptance should therefore be measured separately.
The same applies to requests for human assistance. Seeking clarification is not automatically a failure of the AI pathway; it may demonstrate appropriate use of an available safeguard. An evaluation that rewards only independent completion could miss that distinction.
Follow trust into the next encounter
The pre-visit setting creates an opportunity to examine whether attitudes translate into better communication with the clinician. Did the patient arrive with clearer questions? Did they understand which possibilities remained provisional? Did the clinician need to undo a misunderstanding before assessing the presenting concern?
These are proposed follow-up questions. The favourable attitude finding does not answer them by itself. Nor does a remaining confidentiality concern prove that the service mishandled information. A concern, a comprehension error and a breach are different things and require different evidence.
The most useful result would not necessarily be the highest possible trust score. It might be patients accurately distinguishing what the AI helped with from what still required clinical judgement, while retaining confidence that their concerns would reach a person.
What clinicians and educators can do with this distinction
A practical teaching exercise is to give a learner a fictional AI explanation and ask them to predict the patient's interpretation before seeing any satisfaction rating. Then compare that prediction with feedback from a role-player. The exercise can reveal whether the explanation makes the plan clearer or merely sounds reassuring.
Clinical learning tools can support that discussion, but platform use is not evidence of improved patient trust. The useful educational outcome is the learner's ability to explain uncertainty and check understanding, not the number of favourable comments collected about an interface.
Frequently asked questions
Did AMIE improve patient attitudes towards AI?
The October 2026 abstract reports a positive shift after the AI interaction that remained elevated after the clinical appointment. This is an attitude finding, not a measure of improved health outcomes.
Did favourable experiences remove privacy and trust concerns?
No. BIDMC's October 2026 account reports continuing concerns about confidentiality and aspects of honesty and trustworthiness alongside the positive experience findings.
What should patient-facing AI aim for instead of maximum trust?
It should support appropriate reliance: patients understand the tool's role, its uncertainties and how to obtain human help. That requires testing comprehension as well as satisfaction.